España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Psilocybin
Breaking Taboos: Rabbi Leads Research On Psychedelics And Jewish Identity
Sexual Health: Psychedelics Found To Enhance Function In Imperial College Study
Portland Launches Nation's First Psilocybin Service Center Combining Mindfulness Practices
Sexual Health: Psychedelics Found To Enhance Function In Imperial College Study
Portland Launches Nation's First Psilocybin Service Center Combining Mindfulness Practices
TV News Anchor Kendis Gibson Opens Up About Mental Health Struggles And Psychedelic Therapy In New Memoir
Kelly Slater Talks Psychedelics: Healing Trauma And Unlocking Potential
TV News Anchor Kendis Gibson Opens Up About Mental Health Struggles And Psychedelic Therapy In New Memoir
Kelly Slater Talks Psychedelics: Healing Trauma And Unlocking Potential
Veteran Access To Psychedelic Mental Health Therapies Stalls In Virginia
How To Navigate Difficult Psychedelic Journeys: Research Insights
Read More...
Psilocybin Recent News
Georgia Lawmakers Take First Steps Toward Psychedelic-Assisted Therapy For Veterans
Georgia lawmakers propose $5M for psychedelic research to treat veterans' PTSD, signaling growing acceptance of alternative mental health therapies.
Healthcare Workers Back Psychedelics But Lack Crucial Knowledge, Study Finds
A new study shows U.S. healthcare professionals support psychedelic therapies but face significant knowledge gaps, underscoring a need for formal training.
Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
Patents Reveal New Prodrugs For Psilocin, Promising Reliable Mental Health Treatments
Recent patents on novel psychedelic prodrugs show promise in enhancing stability and efficacy, offering new hope for effective mental health treatments.
Relaxation Emerges As Strongest Predictor Of Psychedelic Therapy Benefits, Study
Study reveals relaxation, not mystical experiences, as the main factor in the success of psychedelic therapy for treatment-resistant depression.
Psychedelic Mushrooms Market Poised For $3.3 Billion Surge By 2031
Psychedelic mushrooms market to reach $3.3 billion by 2031, due to rising demand, regulatory changes & growing psilocybin acceptance.
UK Breaks New Ground With First Government-Backed Psilocybin Therapy For Opioid Crisis
A UK-funded study will explore psilocybin's potential to treat opioid addiction, with a focus on reducing high relapse rates.
Pro Golfers Turn To Psychedelics For Focus Boost And Anxiety Relief
Pro golfers are using psychedelics like psilocybin and DMT to sharpen mental performance, signaling a new trend in sports wellness.
Elon Musk And Joe Rogan Criticize Psychedelics And Big Pharma's Legacy Of Profit Over Public Health
Joe Rogan and Elon Musk discuss the pharma industry's history of prioritizing profits over health, sparking debate on drug safety and ethics.
Americans Favor Psilocybin For Mental Health Treatment, Study Finds
Most Americans support psilocybin use for mental health and well-being, a new study shows, marking a shift in attitudes toward psychedelics.
Psychoanalysis Meets LSD: Argentina's Lost 1950s Era Of Psychedelic Therapy
Explore Argentina's golden era of psychedelic therapy (1957-1967), where LSD and psychoanalysis merged for mental health treatments.
Online Mushroom Market Booms: Experts Say Be Very Careful
Websites selling psilocybin are popping up, betting on legalization. But safety and legal concerns persist as the unregulated market grows.
Magic Mushroom Strains: Is There Really A Difference?
New research suggests magic mushroom strains are more alike than different. Focus on cultivation techniques, not strain names, to enhance potency and effects.
Massachusetts Veterans Advocate For Psilocybin Legalization: Will Voters Support Them?
The Optimism Experiment: Psilocybin's Impact On Motivation
Researchers found psilocybin increased optimism in rats, suggesting potential benefits for treating depression symptoms in humans.
Could Psilocybin Be A Game-Changer For Millions Battling Depression? New Study Says Yes
Over 5 million Americans with depression could be eligible for psilocybin-assisted therapy if FDA-approved, signaling vast market potential.
Missouri Allocates $5M For Psilocybin Research To Treat Opioid Addiction
Missouri dedicates $5M from its opioid settlement fund to psilocybin research for treating opioid addiction, seeking expert input on this project.
Michigan Bill Could Legalize Psychedelic Mushrooms For PTSD Treatment
Michigan introduces a bill to legalize psychedelic mushrooms for PTSD treatment, allowing adults to possess up to two ounces for personal use
Psilocybin Breakthrough: Study Reveals Potential Application For Body Dysmorphic Disorder
New study suggests psilocybin may help treat body dysmorphic disorder by rewiring brain connectivity and reducing obsessive thought patterns.
Minnesota Moves Forward With Psilocybin Therapy Plan, Eyes Broader Psychedelic Reforms
Minnesota's Psychedelic Task Force advances a clinical psilocybin therapy program, with broader decriminalization still under consideration.
DEA Boosts Psychedelics Production For Research, Cannabis Quotas Hold Steady Ahead Of Rescheduling
The DEA increases production quotas for psychedelics like psilocybin and ibogaine, while marijuana quotas remain stable ahead of a possible rescheduling decision.
Psilocybin Found To Be As Effective As Lexapro In Treating Depression, Researchers Say
Psilocybin rivals antidepressants in treating depression while offering long-term well-being benefits, according to a new study.
Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition
Psyence Biomed launches Phase IIb trials for psilocybin in palliative care and Alcohol Use Disorder, bolstering its clinical pipeline with key acquisitions and partnerships.